[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632582":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":31,"collaborators":10,"id":33,"slug":34,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":38,"acronym":10,"eligibilityCriteria":39,"healthyVolunteers":35,"sex":40,"minAge":41,"maxAge":10,"enrollmentInfo":42,"targetDuration":10,"studyType":45,"phases":10,"briefSummary":46,"conditions":47,"keywords":49,"overallStatus":55,"whyStopped":10,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},{"fullName":5,"class":6},"Daewoong Pharmaceutical Co. LTD.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Baroezet Treatment Group",null,"Patients with dyslipidemia who are prescribed Baroezet Tablet 1\u002F10 mg according to routine clinical practice will be observed for approximately 24 weeks.",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Yun Jeong Kong","CONTACT","82-10-3206-5162","yjkong246@daewoong.co.kr",[19],{"facility":20,"status":10,"city":21,"state":10,"zip":10,"country":22,"countryCode":10,"cosmosGeoPoint":23,"geoPoint":28,"contacts":29},"Multiple centers in Republic of Korea","Seoul","South Korea",{"type":24,"coordinates":25},"Point",[26,27],126.9784,37.566,{"lat":27,"lon":26},[30],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},{"type":32,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100632582","efficacy-and-safety-of-baroezet-tablet-in-korean-patients-with-dyslipidemia-a-prospective-observational-study-100632582",false,"NCT07515560","Efficacy and Safety of Baroezet Tablet in Korean Patients With Dyslipidemia: A Prospective Observational Study","A Prospective, Non-interventional, Multi-center Observational Study to Evaluate the Efficacy and Safety of Baroezet Tablet 1\u002F10 mg in Korean Patients With Dyslipidemia","Inclusion Criteria:\n\n* Adults aged ≥19 years\n* Patients diagnosed with dyslipidemia\n* Patients who require treatment with Baroezet Tablet\n* Patients who provide written informed consent\n\nExclusion Criteria:\n\n* Hypersensitivity to study drug components\n* Active liver disease\n* Pregnant or breastfeeding women\n* Patients considered inappropriate by investigator","ALL","19 Years",{"count":43,"type":44},12000,"ESTIMATED","OBSERVATIONAL","This study is a prospective, non-interventional, multi-center observational study to evaluate the efficacy and safety of Baroezet Tablet 1\u002F10 mg in Korean patients with dyslipidemia in real-world clinical practice.\n\nPatients who are prescribed Baroezet Tablet according to the physician's clinical judgment will be followed for approximately 24 weeks. The study will assess changes in lipid profiles, including LDL-C, as well as safety outcomes such as adverse events.",[48],"Dyslipidemia",[48,50,51,52,53,54],"LDL-C","Statin","Ezetimibe","Observational Study","Real-world","NOT_YET_RECRUITING","2026-03-31",{"date":58,"type":59},"2026-04-07","ACTUAL",{"date":61,"type":44},"2026-04-30",{"date":63,"type":44},"2027-12-31",{"name":5,"class":6},1]